Neuroprosthetics

THE CHRISTOPHER & DANA REEVE FOUNDATION ANNOUNCES $3.1M SPINAL CORD INJURY RESEARCH GRANTS

Retrieved on: 
Wednesday, March 6, 2024
Therapy, Blood pressure, SCI, Medicine, Psychology, Arm, Paralysis, BCI, FDA, ARC, Quality of life, Food, Neuroprosthetics, BSI, BDD, Safety, Tetraplegia, CNS, Science, Movement, Research, Medical device

SHORT HILLS, N.J., March 6, 2024 /PRNewswire/ -- The Christopher & Dana Reeve Foundation, a leading nonprofit organization dedicated to curing spinal cord injury by funding innovative research and improving the quality of life for individuals and families impacted by paralysis, announced today three new spinal cord injury (SCI) research grants totaling $3.1 million. The grants support clinical trials and research tools aimed at accelerating the therapeutic development of SCI treatments.

Key Points: 
  • SHORT HILLS, N.J., March 6, 2024 /PRNewswire/ -- The Christopher & Dana Reeve Foundation , a leading nonprofit organization dedicated to curing spinal cord injury by funding innovative research and improving the quality of life for individuals and families impacted by paralysis, announced today three new spinal cord injury (SCI) research grants totaling $3.1 million.
  • The Reeve Foundation is dedicated to developing real-world treatments for people living with spinal cord injury (SCI) and paralysis.
  • Today, as 21st-century technology and cumulative scientific gains converge, we are on the cusp of a new era in spinal cord injury research.
  • "These grants represent a fresh approach to spurring the SCI scientific arena forward through our support of high-risk-high-reward endeavors that address unmet needs of individuals living with spinal cord injury," said Marco Baptista, Ph.D., Chief Scientific Officer of the Reeve Foundation.

BioInnovation Institute & Science Prize for Innovation winners announced

Retrieved on: 
Thursday, April 13, 2023
Blood pressure, Memorial Sloan Kettering Cancer Center, Prize, Swiss Federal Institute of Technology, Honey, Chromosome, University, Tetraplegia, Neuroprosthetics, Breeding, Spinal cord, Cancer, Polymer, MSKCC, Innovation, Research, MIT, University of North Carolina at Greensboro, USD, Associate, Paralysis, Entrepreneurship, Seumas McNally Grand Prize, EPFL, BII, Swiss Federal Institute of Aquatic Science and Technology, SCI, Pharmaceutical industry, Science

The annual award hosted by BioInnovation Institute and Science aims to recognize and celebrate bold researchers who are asking fundamental questions at the intersection of life sciences and entrepreneurship.

Key Points: 
  • The annual award hosted by BioInnovation Institute and Science aims to recognize and celebrate bold researchers who are asking fundamental questions at the intersection of life sciences and entrepreneurship.
  • The three winners will have their essays published in the journal, Science, and will be invited into BII's entrepreneurial ecosystem.
  • In addition, the Grand Prize winner will receive USD 25,000 and each finalist will receive USD 10,000 at a grand award ceremony in Copenhagen, Denmark, April 27th.
  • The BII & Science Prize for Innovation is in its second year, with applications received from around the world.

BioInnovation Institute & Science Prize for Innovation winners announced

Retrieved on: 
Thursday, April 13, 2023
Blood pressure, Memorial Sloan Kettering Cancer Center, Prize, Swiss Federal Institute of Technology, Honey, Chromosome, University, Tetraplegia, Neuroprosthetics, Breeding, Spinal cord, Cancer, Polymer, MSKCC, Innovation, Research, MIT, University of North Carolina at Greensboro, USD, Associate, Paralysis, Entrepreneurship, Seumas McNally Grand Prize, EPFL, BII, Swiss Federal Institute of Aquatic Science and Technology, SCI, Pharmaceutical industry, Science

The annual award hosted by BioInnovation Institute and Science aims to recognize and celebrate bold researchers who are asking fundamental questions at the intersection of life sciences and entrepreneurship.

Key Points: 
  • The annual award hosted by BioInnovation Institute and Science aims to recognize and celebrate bold researchers who are asking fundamental questions at the intersection of life sciences and entrepreneurship.
  • The three winners will have their essays published in the journal, Science, and will be invited into BII's entrepreneurial ecosystem.
  • In addition, the Grand Prize winner will receive USD 25,000 and each finalist will receive USD 10,000 at a grand award ceremony in Copenhagen, Denmark, April 27th.
  • The BII & Science Prize for Innovation is in its second year, with applications received from around the world.

Synchron Announces Publication of Brain-Computer Interface Clinical Trial in JAMA Neurology

Retrieved on: 
Monday, January 9, 2023
Biotechnology, Technology, Health, Biometrics, Wearables, Mobile Technology, Neurology, Health Technology, Medical Devices, Mobile, Wireless, Hardware, Clinical Trials, Clinical trial, Communication, Multiple sclerosis, Partnership, Salt Lake, Stroke, University, Muscle, Royal Melbourne Hospital, Neuroprosthetics, Paralysis, BCIS, Smartphone, Brain, Telephone, Multimedia, Carnegie Mellon University, Neurology, JAMA Neurology, BCI, Digital, Trial of the century, ALS, Acquisition, Angiography, Patient, Ripple, COMMAND, Learning, Safety, Motor cortex, Mount Sinai Hospital, SWITCH, Caregiver, Mobile phone, Management, Medical imaging, Journal of NeuroInterventional Surgery, Beckman Coulter

Synchron , an implantable brain-computer interface (BCI) company, today announced the medical journal JAMA Neurology has published peer-reviewed, long-term safety results from a clinical study in four patients with severe paralysis implanted with Synchron’s first-generation Stentrode™, a neuroprosthesis device.

Key Points: 
  • Synchron , an implantable brain-computer interface (BCI) company, today announced the medical journal JAMA Neurology has published peer-reviewed, long-term safety results from a clinical study in four patients with severe paralysis implanted with Synchron’s first-generation Stentrode™, a neuroprosthesis device.
  • Three out of six participants have been enrolled in the COMMAND trial, two in New York City and one in Pittsburgh.
  • For healthcare providers, patients, or caregivers interested in learning more about our ongoing US clinical trial, email: [email protected] .
  • A BCI could restore motor capability by using the cortical motor signal to bypass impaired limbs and directly control a computer.

Synchron Announces Long-Term Safety Results from Fully Implanted Endovascular Brain-Computer Interface Stentrode™ for Severe Paralysis

Retrieved on: 
Tuesday, March 29, 2022
Health, Medical Devices, General Health, Clinical Trials, Research, Science, Biotechnology, Skull, Blood, 2014 Australian federal budget, National Health, Death, Disability, ALS, Research, Paralysis, Doctor of Philosophy, Neuroprosthetics, Hypertension, CEO, BCI, Nervous system, Office, Technology, Medical Research Council, MS, Epilepsy, Brain, American Academy, Science, Movement, Motor cortex, MNP, University, FDA, Depression, Patient, Silicon, Medical device, Medical imaging, Stent-electrode recording array, MD, Beckman Coulter, THE STENTRODE™, SYNCHRON, INC.

Stentrode also stayed in place for all four patients and the blood vessel in which the device was implanted remained open.

Key Points: 
  • Stentrode also stayed in place for all four patients and the blood vessel in which the device was implanted remained open.
  • Receiving the Stentrode implant allowed participants to use a computer to communicate by text and perform daily tasks such as online shopping and banking.
  • Synchron is the only company to receive FDA approval to conduct clinical trials of a permanently implanted BCI.
  • Synchron, a brain interface platform company, is a leader in the field of implantable neural interface technology.

Synchron Expands Advisory Board as Brain-Computer Interface Device Stentrode™ Advances into Patients in US Clinical Trials

Retrieved on: 
Tuesday, February 22, 2022
GLOBE, Medtronic, Depression, Neuroprosthetics, Lists of diseases, Disorder, Silicon, Movement, The New England Journal of Medicine, Business development, Growth, Bionics, Doctor of Philosophy, University, Neuroscience, Motor cortex, Neurology, UCSF, Brain, Alphabet Inc., Adoption, Epilepsy, Acquisition, BCI, Paralysis, Nervous system, Tremor, Medical device, Skull, Boston Scientific, FDA, Blood, MBA, Hypertension, Patient, MNP, Sonova, Patent, University of California, Neuralink, Research, CEO, Department, Management, Medical imaging, Beckman Coulter, Medical transcription, Stent-electrode recording array, Technology, MD, Science

Weve strengthened our advisory board as we advance our flagship device, the Stentrode, into patients in the US this year, said Thomas Oxley, MD, PhD, CEO of Synchron.

Key Points: 
  • Weve strengthened our advisory board as we advance our flagship device, the Stentrode, into patients in the US this year, said Thomas Oxley, MD, PhD, CEO of Synchron.
  • Synchron has developed an endovascular brain computer interface that is designed to access every corner of the brain using its natural highways, the blood vessels.
  • It takes around two hours to implant a Stentrode device with a minimally invasive procedure.
  • Synchron is the only company to receive FDA approval to conduct clinical trials of a permanently implanted BCI.

Brisbane Lions Honor Two Passionate Lions Fans Who Are Advancing Potential Solutions for MND Patients

Retrieved on: 
Thursday, February 3, 2022
Research, Mental Health, Medical Devices, Surgery, Clinical Trials, Biotechnology, General Health, Health, Science, Other Science, Docklands Stadium, Brisbane Bears, CEO, Patient, Amyotrophic lateral sclerosis, Epilepsy, Silicon, MD, ALS, BCI, Brisbane Lions, AFL, Technology, Stroke, MND, Nervous system, VFL/AFL, Hypertension, Skull, Doctor of Philosophy, Paralysis, Depression, MNP, Fitzroy Football Club, Neuroprosthetics, Multimedia, History, Sclerosis (medicine), Nightclub, Medical device, Amusement park, Beckman Coulter, Stent-electrode recording array, the StentrodeTM, Synchron, Inc., the Brisbane Lions, THE STENTRODETM, SYNCHRON, INC., THE BRISBANE LIONS

OKeefe was honored, along with Synchron CEO Thomas Oxley, MD, PhD, for their contributions to advancing this technological solution for people with MND.

Key Points: 
  • OKeefe was honored, along with Synchron CEO Thomas Oxley, MD, PhD, for their contributions to advancing this technological solution for people with MND.
  • The MND Victoria organization participated in the event and shared its gratitude to both honorees as well as the entire Brisbane Lions football club.
  • We cannot thank the Lions enough for the wonderful surprise and thrill given to Phil today who is just so passionate about the Lions.
  • The Brisbane Lions were formed on 4 July, 1996, when the AFL approved a merger between the Brisbane Bears and the Fitzroy Lions.

Synchron Announces First Direct-Thought Tweet, “Hello World,” Using an Implantable Brain Computer Interface

Retrieved on: 
Thursday, December 23, 2021
Technology, General Health, Health, Other Technology, BCIS, Nervous system, Epilepsy, Technology, Doctor of Philosophy, Amyotrophic lateral sclerosis, Patient, Family, CEO, Twitter, Neuroprosthetics, Stroke, Freedom, MNP, Depression, Silicon, Hypertension, Learning, Paralysis, MD, Skull, Social media, ALS, Hope, Medical imaging, Mobile phone, Medical device, Beckman Coulter, Stent-electrode recording array, the StentrodeTM, Synchron, Inc, THE STENTRODETM, SYNCHRON, INC

Synchron , a brain computer interface company, today announced a Twitter takeover by Philip OKeefe, one of the patients implanted with the Stentrode brain computer interface.

Key Points: 
  • Synchron , a brain computer interface company, today announced a Twitter takeover by Philip OKeefe, one of the patients implanted with the Stentrode brain computer interface.
  • Mr. OKeefe is the first person to successfully message the world on social media directly through thought using an implantable brain computer interface.
  • Mr. OKeefe, a 62-year-old man with amyotrophic lateral sclerosis (ALS), successfully turned his direct thought to text via Twitter when he messaged Hello World using the Stentrode brain computer interface.
  • Synchron, a brain interface platform company, is a leader in the field of implantable neural interface technology.

Neuroprosthetics Market is Expected to Grow at a CAGR of 12.76% and is Anticipated to Reach USD 11.32 Billion by 2026, Estimates DelveInsight

Retrieved on: 
Thursday, November 25, 2021
Patient, Neuroimaging, Lists of diseases, Brain, Boston Scientific, US Foods, DBS, Population, CAGR, LivaNova, Awareness, Neurodegeneration, Robotics, Neuroprosthetics, Prevalence, USD, Argus retinal prosthesis, Human, Food and Drug Administration, Food, COVID-19, Animal, Chronic pain, CRPS, Research, Nerve injury, Injury, BCI, FDA, LAS, Growth, Medtronic, Accident, Sonova, Cochlear Limited, Hearing loss, Nucleus, Pharmaceutical industry, Video game, Medical device

LAS VEGAS, Nov. 25, 2021 /PRNewswire/ -- DelveInsight's Neuroprosthetics Market Insights and Forecast report provides the current and forecast Neuroprosthetics Market, upcoming innovation in the devices, individual market shares, challenges, drivers and barriers, market trends, and key competitors in the Neuroprosthetics Market. 

Key Points: 
  • LAS VEGAS, Nov. 25, 2021 /PRNewswire/ -- DelveInsight's Neuroprosthetics Market Insights and Forecast report provides the current and forecast Neuroprosthetics Market, upcoming innovation in the devices, individual market shares, challenges, drivers and barriers, market trends, and key competitors in the Neuroprosthetics Market.
  • Some of the salient features from the Neuroprosthetics Market report:
    As per an analysis by DelveInsight, North America is expected to dominate the overall Neuroprosthetics Market during the forecast period.
  • DelveInsight estimates that the Global Neuroprosthetics Market was valued at USD 6.35 billion in 2020, growing at a CAGR of 12.76% during the forecast period from 2021 to 2026 and is anticipated to reach USD 11.32 billion by 2026.
  • To get a deeper understanding of the driving factors related to the Neuroprosthetics Market, get a snapshot of the Neuroprosthetics Market Dynamics

Insights on the Neurostimulation Devices Global Market to 2026 - Rise in Number of People Suffering from Hearing Loss is Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, September 6, 2021
Medical Devices, Health, Medical technology, Branches of biology, Health sciences, Medical devices, Audiology, Otology, Neurotechnology, Neuroprosthetics, Neurostimulation, Implant, Hearing loss, Hearing aid

Neurostimulation is used as a key element in neural prosthetics for hearing aids, artificial vision, artificial limbs, brain-machine interfaces, etc.

Key Points: 
  • Neurostimulation is used as a key element in neural prosthetics for hearing aids, artificial vision, artificial limbs, brain-machine interfaces, etc.
  • the growth in the neurostimulation devices market may be attributed to the increasing prevalence of chronic neuromuscular disorder and the rising adoption of these devices by the physicians.
  • However, stringent regulations of the neurostimulation devices and lack of skilled professionals for performing the surgeries might restrain the market growth during the given time frame.
  • The market is expected to surge in the coming years, due to the rise in the number of people, suffering from hearing loss and other related concerns.